Chargement des cours...
Prévisions
L'objectif de cours moyen des analystes est de 18,85 € (+45,34 %). La médiane est de 19,16 € (+47,73 %).
| Acheter |
9 |
| Conserver |
2 |
| Vendre |
0 |
Discussions dans la communauté
Il n'y a pas encore de discussion sur cet actif.
Lancer une discussionActualités Accéder au fil d'actualités
Erasca places shares for $550 million at $17.50 per share
Erasca placed 31,428,572 common shares at $17.50 per share and expects gross proceeds of about $550 million. The lead managers were granted a 30-day option to purchase up to 4,714,285 additional shares at the offering price. Net proceeds are intended to finance research and development, ongoing development programs and working capital; the closing of the transaction is expected on July 15, 2026. » Plus sur de.investing.com
Erasca plans $500 million capital raise despite positive phase‑1 data
Erasca announced a guaranteed public placement of common stock totaling $500 million plus a 30‑day option for $75 million; the proceeds are intended for R&D and working capital, which triggered shareholder dilution concerns and sent the stock down about 3.1% in after‑hours trading. At the same time the company released updated phase‑1 data for ERAS‑0015: an unconfirmed overall response rate of 57% at eight weeks in patients with ductal pancreatic cancer and KRAS‑G12X mutation; recommended dose 32 mg once daily, with six of seven patients remaining on treatment. Goldman Sachs initiated coverage with an "Early‑Stage Biotech" rating and views Erasca as a leader in RAS targeting behind Revolution Medicines; ongoing litigation and a weak market backdrop heighten near‑term risks. » Plus sur de.investing.com
Erasca plans $500 million share offering to finance research
Erasca intends to issue common shares in a syndicated public offering totaling $500 million and to grant the bookrunners a 30-day option to purchase additional shares worth up to $75 million. The securities will be offered under an S-3 shelf registration; J.P. Morgan, Morgan Stanley, Jefferies and Evercore ISI are leading the syndicate. Net proceeds and existing cash will be used to fund research and development, working capital and general corporate purposes. The announcement follows a strong share rally and a market capitalization of about $5.57 billion; the stock is rated overvalued in the analysis and the company remains unprofitable (EPS -$0.96). » Plus sur de.investing.com
Erasca reports positive phase 1 data for RAS inhibitor ERAS‑0015
Erasca released preliminary phase 1 results for the oral pan‑RAS inhibitor ERAS‑0015: in the AURORAS‑1 study, seven PDAC patients with KRAS G12X showed an unconfirmed overall response rate of 57% at eight weeks. The recommended dose for the expansion phase is 32 mg once daily; treatment‑related adverse events were mostly mild, with no dose‑limiting toxicities or treatment‑related discontinuations. Combination data with panitumumab showed no DLTs in the 16 mg cohort; Erasca plans phase 3 trials in PDAC and RAS‑mutant NSCLC for 2027/2028 and expects further data in H1 2027. The positive results contributed to a strong share price increase and a market capitalization of about $5.57 billion. » Plus sur de.investing.com
Erasca bets on drug candidate ERAS‑0015 despite earlier setbacks
Erasca is a development-only precision oncology company without any revenue base, whose future depends on the success of its flagship candidate ERAS‑0015. After a death in an early trial and a patent dispute, the stock suffered significant losses in spring 2026, but market value still stood at over USD 5.7 billion in July 2026. The business model remains based on venture capital and partnerships, while the clinical progress of ERAS‑0015 will determine further growth. » Plus sur finanzen.net
Données financières de l'entreprise
| (EUR) | septembre 2026 | YoY |
|---|---|---|
| Chiffre d'affaires | 0 | - |
| Bénéfice brut | 0 | - |
| Bénéfice net | -45,32 M | 73,73 % |
| EBITDA | -44,69 M | 75,65 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 4,45 Md € |
Nombre d'actions | 350,96 M |
Plus haut/bas sur 52 semaines | 22,15 € - 2,51 € |
| Dividendes | Non |
Bêta | 0,65 |
Ratio P/E | -14,03 |
Ratio PEG | 0,13 |
Ratio P/B | 5,22 |
Ratio P/S | 0,00 |
Profil de l'entreprise
Erasca, Inc., une société biopharmaceutique au stade clinique, se concentre sur la découverte, le développement et la commercialisation de thérapies destinées aux patients atteints de cancers liés à la voie RAS/MAPK. Les principaux candidats de la société comprennent l'ERAS-007, un inhibiteur oral de ERK1/2 destiné au traitement du cancer du poumon non à petites cellules, du cancer colorectal et de la leucémie myéloïde aiguë ; et l'ERAS-601, un inhibiteur oral de SHP2 destiné aux patients atteints de tumeurs solides avancées ou métastatiques. Elle développe également l'ERAS-801, un inhibiteur d'EGFR pénétrant le système nerveux central, destiné au traitement des patients atteints de glioblastome multiforme récurrent. La société a été constituée en 2018 et a son siège social à San Diego, en Californie.
| Nom | ERASCA INC. DL -,0001 Aktie |
| PDG | Jonathan E. Lim |
| Siège social | San Diego,
ca États-Unis |
| Site web | |
| Secteur | Matériaux |
| Industrie | Produits chimiques |
| Introduction en bourse | 16/07/2021 |
| Employés | 103 |
Symboles boursiers
| Bourse | Symbole |
|---|---|
NASDAQ | ERAS |